Who Paid My Doc
Nexplanon
Drug Etonogestrel
NDC 78206-145-01
General payments
$13,823,641
Research payments
$3,391,281
Through program year 2025, $13,823,641 in general payments and $3,391,281 in research payments were reported against Nexplanon (Etonogestrel).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $2,292,040 | 22,429 |
| 2024 | General | $2,190,394 | 22,228 |
| 2023 | General | $3,883,565 | 27,366 |
| 2023 | Research | $964,736 | 13 |
| 2022 | General | $5,457,642 | 32,719 |
| 2022 | Research | $2,426,545 | 523 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 94 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 54 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
104,742 general · 536 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.